CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets
F-FR-60000-023
Phase 2 small_molecule active
Quick answer
CABOMETYX 60 mg film-coated tablets, CABOMETYX 40 mg film-coated tablets, CABOMETYX 20 mg film-coated tablets for Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors is a Phase 2 program (small_molecule) at Ipsen Pharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Ipsen Pharma
- Indication
- Unresectable, Locally Advanced or Metastatic Renal Cell Carcinoma with a Clear-Cell Component Who Progressed After 1st Line Treatment with Checkpoint Inhibitors
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active